What is SPRAVATO® (esketamine) CIII nasal spray?

SPRAVATO® is a prescription medicine used:

• with or without an antidepressant taken by mouth, to treat adults with treatment-resistant depression (TRD).
• with an antidepressant taken by mouth, to treat depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions.

SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.

It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.

It is not known if SPRAVATO® is safe and effective in children.

SPRAVATO® is the only nasal spray treatment indicated for people who’ve taken two or more oral antidepressants and still experience symptoms of depression, or TRD.

SPRAVATO® is an N-methyl-D-aspartate (NMDA) receptor antagonist that is believed to work differently by acting on a pathway in the brain where glutamate, a brain chemical, works with other brain chemicals to balance well-being and depression.

The exact way SPRAVATO® works is not fully understood.

• SPRAVATO® is administered twice a week for the first four weeks.
• After the first four weeks, you and your healthcare provider will discuss and determine if treatment should be continued, the dose, and how often you’ll receive SPRAVATO®.